WO1995026191A1 - Injizierbare lösungen von dirithromycin - Google Patents
Injizierbare lösungen von dirithromycin Download PDFInfo
- Publication number
- WO1995026191A1 WO1995026191A1 PCT/EP1995/001096 EP9501096W WO9526191A1 WO 1995026191 A1 WO1995026191 A1 WO 1995026191A1 EP 9501096 W EP9501096 W EP 9501096W WO 9526191 A1 WO9526191 A1 WO 9526191A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dirithromycin
- injection
- solution
- ethanol
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- Dirithromycin is a partially synthetic antibiotic from the Erythromycine series. Dirithromycin, process for its preparation and its use as a medicinal product was first described in German Offenlegungsschrift P 25 15 075. It is usually applied in the form of solid oral preparation, since it has some problematic properties with regard to its stability in solutions. In aqueous solutions, it decomposes very quickly to erythromycylamine. Correspondingly, aqueous injection solutions are not stable and are not yet known.
- Lipophilic injection solutions usually contain liquid fatty acid esters such as isopropyl myristate and ethyl oleate as well as triglycerides (triacetin) and optionally amphiphilic or hydrophilic organic solvents such as ethanol, propanediol, benzyl alcohol and solketal.
- liquid fatty acid esters such as isopropyl myristate and ethyl oleate
- triglycerides triacetin
- amphiphilic or hydrophilic organic solvents such as ethanol, propanediol, benzyl alcohol and solketal.
- dirithromycin-containing, single-phase, water-containing lipophilic (oily) injection solutions which contain a defined amount of water are claimed.
- the maximum proportion of water is determined by the specification of a single-phase system. Studies have shown that the instant the two-phase system is formed by the addition of water, the stability of the dirithromycin is drastically reduced. The conditions under which a second phase forms when water is added depends on the composition of the lipophilic solution for injection. Solutions with a high proportion of long-chain hydrophobic or amphiphilic components already form a two-phase system with a 3% water content, while mixtures with short-chain hydrophobic components, such as triacetin / ethanol, also form single-phase systems with a 20% water content .
- the transition to two-phase solvent mixtures preference is given to single-phase solvent mixtures which have a maximum water content, the transition to two-phase solvent mixtures to be regarded as the critical limit.
- the maximum proportion of water that can be added depends on the proportion of the hydrophilic or amphiphilic solvent - in a preferred embodiment ethanol - in the solvent mixture.
- the water content can be a maximum of approx. 10 - 12% by weight based on the ethanol content.
- the greater the proportion of ethanol the higher the maximum amount of water that can be added before the critical limit of the transition to the two-phase system is reached.
- hydrophilic solvent - for example ethanol - is limited by two factors, on the one hand, dirithromycin is unstable in pure ethanol / water systems, and on the other hand, the injection of injection solutions with a high proportion of ethanol is very painful.
- a still acceptable upper limit is seen at approximately 50% by weight ethanol, a range between 30 and 40% by weight being preferred and between 32 and 37% by weight being particularly preferred.
- a lower limit of hydrophilic solvent - in particular ethanol - which can vary widely in individual cases results from the stipulation that in a preferred embodiment of the active ingredient-containing injection solution, the concentration of dirithromycin should be approximately at least 20 g / 100 ml.
- Solvent mixtures which contain, for example, triacetin as an oily component, permit a higher percentage of water with a low content of hydrophilic solvent (for example ethanol). Corresponding correlations can be found in the tables in the examples.
- oils and fatty acid esters in oily solution mixtures are medium-chain triglycerides (e.g. Miglyol®812), soybean oil, castor oil, sunflower oil, isopropyl palmitate, isopropyl myristate, oleic acid oleate ester (Cetiol®), peanut oil and other vegetable oils. Isopropyl myristate, ethyl oleate and triacetin are preferred.
- Preferred hydrophilic solvents are propanediol, benzyl alcohol, polyethylene glycols and solketal; ethanol is particularly preferred.
- the solutions of dirithromycin according to the invention are stable and can be used over a longer period of at least 6-12 months, and under suitable storage conditions up to several years.
- Triacetin / ethanol system Triacetin / ethanol system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7524954A JPH09510722A (ja) | 1994-03-26 | 1995-03-23 | 注射可能なジリスロマイシン溶液 |
AU22141/95A AU2214195A (en) | 1994-03-26 | 1995-03-23 | Injectable solutions of dirithromycin |
EP95915148A EP0754047A1 (de) | 1994-03-26 | 1995-03-23 | Injizierbare lösungen von dirithromycin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4410637.8 | 1994-03-26 | ||
DE4410637A DE4410637C1 (de) | 1994-03-26 | 1994-03-26 | Injizierbare Lösungen von Dirithromycin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995026191A1 true WO1995026191A1 (de) | 1995-10-05 |
Family
ID=6514000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/001096 WO1995026191A1 (de) | 1994-03-26 | 1995-03-23 | Injizierbare lösungen von dirithromycin |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0754047A1 (de) |
JP (1) | JPH09510722A (de) |
AU (1) | AU2214195A (de) |
CO (1) | CO4370014A1 (de) |
DE (1) | DE4410637C1 (de) |
WO (1) | WO1995026191A1 (de) |
ZA (1) | ZA952405B (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2616047A4 (de) * | 2010-09-16 | 2016-04-27 | Lg Life Sciences Ltd | Nichtwässrige und ölige injektionsformulierung mit konservierungswirkung |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19518917A1 (de) * | 1995-05-23 | 1996-11-28 | Boehringer Ingelheim Vetmed | Stabile, konzentrierte lokalverträgliche Erythromycylamin-Lösungen |
DE19701949A1 (de) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4048306A (en) * | 1975-04-07 | 1977-09-13 | Boehringer Ingelheim Gmbh | Aldehyde-erythromycylamine condensation products |
US4918108A (en) * | 1982-03-16 | 1990-04-17 | Boehringer Ingelheim Vetmedica Gmbh | Method of improving the absorption of injected antibacterial substances |
WO1990014094A1 (en) * | 1989-05-26 | 1990-11-29 | Abbott Laboratories | Injectable clarithromycin composition |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3209429A1 (de) * | 1982-03-16 | 1983-10-06 | Boehringer Ingelheim Vetmed | Mittel zur verbesserung der resorption von injizierten antibakteriell wirksamen substanzen und kombinationen, enthaltend ein benzyaminderivat |
-
1994
- 1994-03-26 DE DE4410637A patent/DE4410637C1/de not_active Expired - Fee Related
-
1995
- 1995-03-23 JP JP7524954A patent/JPH09510722A/ja active Pending
- 1995-03-23 AU AU22141/95A patent/AU2214195A/en not_active Abandoned
- 1995-03-23 CO CO95011794A patent/CO4370014A1/es unknown
- 1995-03-23 EP EP95915148A patent/EP0754047A1/de not_active Withdrawn
- 1995-03-23 WO PCT/EP1995/001096 patent/WO1995026191A1/de not_active Application Discontinuation
- 1995-03-24 ZA ZA952405A patent/ZA952405B/xx unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4048306A (en) * | 1975-04-07 | 1977-09-13 | Boehringer Ingelheim Gmbh | Aldehyde-erythromycylamine condensation products |
US4918108A (en) * | 1982-03-16 | 1990-04-17 | Boehringer Ingelheim Vetmedica Gmbh | Method of improving the absorption of injected antibacterial substances |
WO1990014094A1 (en) * | 1989-05-26 | 1990-11-29 | Abbott Laboratories | Injectable clarithromycin composition |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2616047A4 (de) * | 2010-09-16 | 2016-04-27 | Lg Life Sciences Ltd | Nichtwässrige und ölige injektionsformulierung mit konservierungswirkung |
Also Published As
Publication number | Publication date |
---|---|
EP0754047A1 (de) | 1997-01-22 |
ZA952405B (en) | 1995-09-26 |
CO4370014A1 (es) | 1996-10-07 |
DE4410637C1 (de) | 1995-09-21 |
AU2214195A (en) | 1995-10-17 |
JPH09510722A (ja) | 1997-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69734742T2 (de) | Arzneizusammensetzungen enthaltend Ascomycinderivate | |
DE69816335T2 (de) | Cyclosporin-enthaltende mikroemulsion-vorkonzentratzusammensetzung | |
DE2907460C2 (de) | ||
DE69522227T2 (de) | Öl-im-wasser-emulsionen enthaltend taxin (taxol) und verfahren | |
DE60018372T2 (de) | Oralzusammensetzung als mikroemulsion von silybin | |
DE60014162T2 (de) | Fenofibrathaltige galenische arzneizusammensetzungen und verfahren zu ihrer herstellung | |
DE69815659T2 (de) | Zusammensetzung zur kontrollierten freisetzung | |
DE69525019T2 (de) | Cyclosporin enthaltende Weichkapselzusammensetzungen | |
DE69711267T2 (de) | Cyclosporin enthaltende Weichkapselpräparate | |
DD203464A5 (de) | Verfahren zur herstellung einer verbesserten oel-in-wasser-formulierung von 9-(2-hydroxy-aethoxymethyl)-guanin fuer lokale anwendung | |
CH643456A5 (de) | Pharmazeutische zubereitung. | |
DE69302396T2 (de) | Antiviral wirksame pharmazeutische öl in wasser-emulsion, die 9-[(2-hydroxyethoxy)methyl]-guanin (acyclovir) oder ein salz oder einen ester davon enthält | |
WO1999025332A1 (de) | Zusammensetzung mit azelainsäure | |
WO2000040236A1 (de) | Taxane enthaltende stabile und sterile emulsion und verfahren zu ihrer herstellung | |
DE3408362C2 (de) | Arzneimittel mit antineoplastischer Wirkung | |
DE4410637C1 (de) | Injizierbare Lösungen von Dirithromycin | |
DE69705107T2 (de) | Dermokosmetisches mittel enthaltend retinal | |
DE68906513T2 (de) | Topisch anzuwendende diclofenac enthaltende arzneizubereitungen. | |
DE69428967T2 (de) | Pharmazeutische emulsionen, die bioaktive steroide enthalten | |
DE60036137T2 (de) | Selbstemulgierende formulierung mit erhöhter bioverfügbarkeit und immunsupprimierender wirkung | |
EP0120262B1 (de) | Pharmazeutische Zubereitung mit Retardwirkung | |
WO1999003474A1 (de) | Verfahren zum herstellen von stabilen acetylsalicylsäure-lösungen | |
DE69418892T2 (de) | Selbstemulgierende formulierung zur bildung einer öl-in-wasser-emulsion | |
DE2654709B2 (de) | Verfahren zum Stabilisieren von Baldrianextraktpräparaten | |
WO2000016770A1 (de) | Taxane enthaltende pharmazeutische zubereitung und verfahren zu ihrer herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP KR MX PL RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995915148 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1996 718586 Date of ref document: 19961031 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1995915148 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995915148 Country of ref document: EP |